Equities

Sana Biotechnology Inc

SANA:NSQ

Sana Biotechnology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.62
  • Today's Change0.33 / 7.69%
  • Shares traded1.43m
  • 1 Year change+5.24%
  • Beta1.4913
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sana Biotechnology, Inc. is a biotechnology company focusing on utilizing engineered cells as medicines. It is engaged in developing cell engineering programs to revolutionize treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune and central nervous system disorders. It develops a pipeline of clinical product candidates focused on creating transformative ex vivo therapies across a range of therapeutic areas. Its pipeline includes SC291, SC262, SC255, C379, SC451 and UP421. It is applying its hypoimmune technology to donor derived T cells to be used as allogeneic cell therapies for hematologic malignancies. It is developing SC255, a B-cell maturation antigen-directed allogeneic CAR T, for the treatment of multiple myeloma. It is developing SC262, its hypoimmune-modified CD22-directed allogeneic CAR T program, initially as a potential treatment for patients with relapsed and/or refractory B-cell malignancies.

  • Revenue in USD (TTM)0.00
  • Net income in USD-244.90m
  • Incorporated2018
  • Employees328.00
  • Location
    Sana Biotechnology Inc188 East Blaine Street, Suite 400SEATTLE 98102United StatesUSA
  • Phone+1 (206) 701-7914
  • Fax+1 (302) 636-5454
  • Websitehttps://sana.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
4D Molecular Therapeutics Inc20.22m-109.89m874.13m201.00--1.48--43.23-2.22-2.220.43511.330.0416----137,544.20-22.60-32.67-23.39-34.90-----543.51-617.15----0.00--562.297.966.19--46.26--
89bio Inc0.00-174.61m880.11m70.00--1.69-----1.97-1.970.004.910.00----0.00-32.50-45.50-34.68-49.31------------0.0465-------39.37---36.58--
Tango Therapeutics Inc42.51m-116.49m887.16m140.00--3.58--20.87-1.11-1.110.40682.310.1118----303,635.70-30.62---35.13-------274.04------0.00--46.93--5.95------
Oruka Therapeutics Inc0.00-7.20m888.26m4.00--0.9419-----5.97-5.970.0026.940.00----0.00-19.22-27.78-19.99-29.38------------0.00------46.21------
Zymeworks Inc62.71m-112.51m889.51m290.00--2.20--14.19-1.52-1.520.85315.690.1122--1.55230,533.10-20.13-22.58-23.21-26.90-----179.42-91.17----0.00008---81.577.47-195.44--3.58--
Perspective Therapeutics Inc-1.87m-49.02m900.16m116.00--2.64-----1.39-1.75-0.04375.06-0.0074-----16,086.21-19.37---20.14--------------0.005--------------
Applied Therapeutics Inc-333.00k-161.09m901.54m31.00--12.45-----1.52-1.52-0.00290.6303-0.0039-----13,320.00-187.94-140.37-467.74-240.93-------4,476.42----0.00-------45.15------
MiMedx Group Inc340.46m89.67m907.28m895.0012.375.409.252.660.49960.46222.081.151.672.706.69380,402.3048.16-4.1460.79-5.9083.4183.6128.76-2.703.2213.060.1028--20.03-2.19310.29---26.47--
Immunome Inc10.78m-262.59m930.84m55.00--3.66--86.32-5.64-5.640.25914.230.0639----196,072.70-155.54-94.54-193.54-112.66-----2,435.02-1,403.15----0.00-------184.68--29.52--
Sana Biotechnology Inc0.00-244.90m954.38m328.00--2.81-----1.15-1.150.001.530.00----0.00-36.94-38.99-42.11-42.70------------0.00-------5.11--112.71--
Nuvation Bio Inc1.44m-510.72m970.86m167.00--2.47--676.56-2.11-2.110.00642.430.0023--0.421628,137.26-82.63-16.27-87.18-16.656.13---35,590.24------0.0214------27.25------
IGM Biosciences Inc2.91m-220.40m987.66m204.00--8.06--339.28-3.67-3.670.04852.070.0071----12,995.54-53.94-44.66-59.96-48.20-----7,571.35-23,668.96----0.00--99.25---11.45--73.48--
Cullinan Therapeutics Inc0.00-142.16m998.94m85.00--1.52-----3.10-3.100.0011.340.00----0.00-23.96-12.37-24.85-12.93-------1,026.78----0.00-------237.72---4.44--
Aurinia Pharmaceuticals Inc207.11m-50.35m1.01bn300.00--2.78--4.89-0.3508-0.35081.442.550.38620.80069.20690,350.00-9.39-25.97-10.78-28.2486.08---24.31-137.644.82--0.1778--30.95227.9027.88--57.11--
Enliven Therapeutics Inc0.00-82.83m1.03bn52.00--3.37-----1.93-1.930.006.460.00----0.00-26.91-42.26-28.35-46.62------------0.00-------4,910.75------
Data as of Sep 19 2024. Currency figures normalised to Sana Biotechnology Inc's reporting currency: US Dollar USD

Institutional shareholders

38.70%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Jun 202422.34m10.04%
The Vanguard Group, Inc.as of 30 Jun 202412.50m5.62%
Baillie Gifford & Co.as of 30 Jun 202410.57m4.75%
Canada Pension Plan Investment Boardas of 30 Jun 202410.18m4.57%
BlackRock Fund Advisorsas of 30 Jun 20249.55m4.29%
SSgA Funds Management, Inc.as of 30 Jun 20246.36m2.86%
Capital Research & Management Co. (World Investors)as of 30 Jun 20245.45m2.45%
Crestline Management LPas of 30 Jun 20243.23m1.45%
T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 20243.03m1.36%
Geode Capital Management LLCas of 30 Jun 20242.89m1.30%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.